# EVX-B3

Type: Company

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/evx-b3
Canonical HTML page: https://gethealthbrief.com/entity/evx-b3

## Timeline

- **2026-08-11**: Argus raises Merck price target — Argus lifts its Merck target from $130 to $145 with a Buy rating, citing pipeline depth and clinical progress.
- **2026-08-10**: Merck discloses Evaxion stake — Merck reports holding 1,214,126 shares of Evaxion A/S in a regulatory filing.
- **2025-09**: Merck exercises EVX-B3 option — Merck decides to in-license Evaxion's discovery-stage AI-derived vaccine candidate EVX-B3 against an undisclosed bacterial pathogen.

## Recent coverage (1 stories)

### Merck Takes 1.2M-Share Stake in AI Vaccine Firm Evaxion
2026-08-22 13:50:46 · Sentiment: Positive · Impact: 6/10 · Sources: 2

Merck's disclosure of a 1.21 million-share stake in Evaxion A/S signals growing pharma confidence in AI-discovered vaccine candidates. For health systems, the partnership could accelerate a new class of antigen-targeted vaccines for bacterial pathogens.
Full story: https://gethealthbrief.com/story/merck-stake-evaxion-ai-vaccine-health

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.